A standardized system can simplify, streamline, and ruggedize the mounting of tools, instrumentation, and other equipment in the healthcare setting.
Our client is currently developing a revolutionary new transdermal drug delivery system that leverages the benefits of ultrasound.
ur client is currently developing a new functionalized silica nanoparticle as a drug delivery vector for nucleic acid payloads.
Our client wishes to acquire injectable products that are currently marketed in Germany.
Our client has developed a digital signal processing algorithm and system that effectively removes undesired audio from television programming.
Our client is identifying pharmaceuticals for in-licensing, supply, and tech transfer with regional exclusivity in Saudi Arabia.
Both ABSOLVE and ABSCENT have been evaluated in the clinic and have been more effective / better tolerated than other obesity therapeutics.
Average weight loss is 10 lbs. during the first month’s use (observed range = 4 lbs. to 15 lbs.) and 2 lbs. to 10 lbs. per month thereafter.
ABSOLVE’s APIs are both components of other diet medicines.
First in class, disease-modifying, once a year infusion for osteoarthritis. Company seeking investment
Our client is a pharmaceutical company seeking US FDA and/or EMA approved Prescription (Rx) Drugs and Medical Foods for the Swiss market in Oncology, Hematology, Infectious Disease, Hepatology, Gastrology, Transplant, Hematology, and Hepatology.
Our client has developed a subcutaneous testosterone implant system that overcomes disadvantages with competing HRT products.